提醒

Acrivon Therapeutics Inc. (ACRV)

NasdaqGM: ACRV · 实时价格 · USD

2.06

-0.09 (-4.19%)

收盘价： Aug 28, 2026, 3:59 PM

2.06

+0.00%

盘后: 7:58 PM

股价、关键数字和最新消息，都在这一页。

-4.19% (1D)

买价	1.14
市值	88.28M
营收（TTM）	n/a
净利润（TTM）	-74.22M
	1.86
	-1.88
	n/a
	-1.22
市净率（TTM）	1.02
市销率（TTM）	n/a
财报日期	Aug 14, 2025

卖价	2.06
成交量	151,854
20日均量	404,125
开盘价	2.15
前收盘价	2.15
日内区间	2.06 - 2.19
52周区间	1.27 - 3.56
分析师	Strong Buy
目标价	10.5 (409.71%)
分红	n/a
除息日	n/a

关于 ACRV

Acrivon Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops oncology medicines for patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its generative phosphoproteomics platform. The company operates Acrivon Predictive Precision Proteomics (AP3), a precision medicine platform that enables the creation of drug specific proprietary OncoSignature companion diagnostics that are ...

[阅读更多]

行业 Biotechnology

板块 Healthcare

上市日期 Nov 15, 2022

员工人数 74

交易所 NasdaqGM

股票代码 ACRV

官网 https://acrivon.com

公司完整简介

财务表现

2025年，Acrivon Therapeutics的营收为0，较上一年的0增长undefined%。净利润为-77.91M，下降-3.29%。

财务报表

分析师预测

根据6位分析师的评级，ACRV的平均评级为“Strong Buy”。12个月目标价为10.5，较最新价格上涨空间409.71%。

股票预测

财报意外

Acrivon Therapeutics 已于 Aug 12, 2026 发布季度财报：

营收为 $0 低于预期 $0, ， NaN% 同比增长.
每股收益为 -0.43 超出预期 0.07, ， 21.82% 同比增长.

下次财报发布时间

Acrivon Therapeutics Inc. 的下次财报预计于 Aug 14, 2025, 收盘后。
分析师预计营收为 ... 升级

新闻

4天前 · Zacks

Here's Why Acrivon Therapeutics, Inc. (ACRV) is a Great Momentum Stock to Buy

Does Acrivon Therapeutics, Inc. (ACRV) have what it takes to be a top stock pick for momentum investors? Let's find out.

5月前 · Zacks

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's Why

Acrivon Therapeutics, Inc. (ACRV) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

6月前 · MarketBeat

Acrivon Therapeutics Conference Highlights ACR-368 Phase 2B Data, 52% ORR in Serous Endometrial Cancer

Acrivon Therapeutics (NASDAQ:ACRV) hosted a webcast featuring a key opinion leader (KOL) panel focused on the company’s ongoing ACR-368 registrational-intent Phase 2B study in endometrial cancer, with...

7月前 · Simply Wall St.

Penny Stocks To Watch In January 2026

As the U.S. markets grapple with recent declines and rising Treasury yields, investors are keenly observing potential opportunities in various sectors. Penny stocks, while often seen as relics of past...

7月前 · Simply Wall St.

Co-Founder of Acrivon Therapeutics Peter Blume-Jensen Buys 2.6% More Shares

Even if it's not a huge purchase, we think it was good to see that Peter Blume-Jensen, the Co-Founder of Acrivon...

第 1 页，共 2 页

Acrivon Therapeutics Inc. (ACRV)